摘要
目的评价阿德福韦酯治疗黎族慢性乙型肝炎(CHB)患者疗效与乙型肝炎病毒(HBV)基因型的关系。方法 42例HBeAg阳性、HBVDNA>105copies/ml、ALT>2倍正常值上线的黎族CHB患者,每天口服阿德福韦酯胶囊10mg,治疗48周。在治疗前及治疗后48周,动态观察HBeAg、HBVDNA和ALT的变化。结果 42例患者中,HBVC型是优势基因型(57.14%),其次为B型(38.10%),也有D型(2.38%)和C+D型混合感染(2.38%)的存在。经阿德福韦酯胶囊治疗48周后,B型患者HBeAg阴转率(37.50%)、病毒应答率(56.25%)和血清ALT复常率(62.50%)均高于C型的29.17%、50.00%和54.17%,但两组比较差异无统计学意义(P>0.05)。结论 HBVC型是海南岛黎族HBeAg阳性CHB患者的优势基因型,HBV基因型可能对阿德福韦酯的治疗效果无影响。
Objective To study correlation between HBV genotype and the antiviral efficacy of adefovir dipivoxil on Li ethnic patients with chronic hepatitis B（CHB）.Methods Totally 42 patients with CHB were enrolled in the study.All the patients were treated with adefovir dipivoxil orally 10 mg per day for 48 weeks.HBV genotype was determined by real time polymerase chain reaction.Before treatment and after treatment,serum levels of HBV DNA,HBeAg and ALT were detected.Results The prevalent rates of genotype B,genotype C,genotype D,and genotype C＋D were 57.14%,38.10%,2.38% and 2.38%,respectively.Seroconversion of HBeAg,viral response rate and ALT retention rate were not significant different between genotype B group and genotype C group（P〉0.05）.Conclusion Among the Li ethnic patients with CHB,genotype C was the major HBV genotype.HBV genotypes may not correlate with the antiviral efficacy of adefovir dipivoxil.
出处
《热带医学杂志》
CAS
2011年第9期1021-1022,1039,共3页
Journal of Tropical Medicine
基金
海南省卫生厅基金(琼卫-200548)
海南省卫生厅基金(200852)
关键词
黎族
乙型肝炎病毒
基因型
阿德福韦酯
Li nationality
hepatitis B virus
genotype
adefovir dipivoxil
